Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | YWHAG | P61981 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495444 | 0.85 | TP53 (0.41) | TP53KDM4ESCDALDH1A1SMN1; SMN2 | |
| SCHEMBL3495362 | 0.85 | NAMPT (0.40) | TP53KDM4EHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL3495640 | 0.85 | IDO1 (0.38) | TP53KDM4EMAPTHSD17B10PDE10A | |
| SCHEMBL4965568 | 0.82 | POLB (0.39) | TP53KDM4EALDH1A1SMN1; SMN2POLB | |
| SCHEMBL14302890 | 0.81 | KDM4E (0.43) | TP53KDM4EALDH1A1SMN1; SMN2POLB | |
| SCHEMBL3496814 | 0.79 | HTT (0.39) | TP53KDM4EALDH1A1SMN1; SMN2POLB | |
| SCHEMBL3496608 | 0.78 | KDM4E (0.39) | TP53KDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3495940 | 0.78 | MEN1 (0.43) | TP53MAPTALDH1A1POLBMEN1 | |
| SCHEMBL4964868 | 0.76 | CYP19A1 (0.39) | TP53KDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3494396 | 0.76 | POLB (0.40) | TP53POLBFSCN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | claimed |
| EP-1751157-B1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER (US) | 2007-10-03 | — | — | EP | claimed |
| EP-1751157-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2007-02-14 | — | — | EP | claimed |
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC. | 2005-12-15 | — | — | US | claimed |
| WO-2005103051-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1873155-A1 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1873155-A1 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1751157-B1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1751157-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005103051-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | TP53 537/4885KDM4E 821/4885MAPT 600/4885 |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, INTS9, TYMP | TP53 537/4885KDM4E 821/4885MAPT 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.